136 related articles for article (PubMed ID: 7660877)
1. Synergistic interaction between cisplatin and gemcitabine in ovarian and colon cancer cell lines.
Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Peters GJ
Adv Exp Med Biol; 1994; 370():139-43. PubMed ID: 7660877
[No Abstract] [Full Text] [Related]
2. Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC).
Kroep JR; van Moorsel CJ; Veerman G; Voorn DA; Schultz RM; Worzalla JF; Tanzer LR; Merriman RL; Pinedo HM; Peters GJ
Adv Exp Med Biol; 1998; 431():657-60. PubMed ID: 9598147
[No Abstract] [Full Text] [Related]
3. Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
Ruiz van Haperen VW; Veerman G; Eriksson S; Stegmann AP; Peters GJ
Semin Oncol; 1995 Aug; 22(4 Suppl 11):35-41. PubMed ID: 7481843
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of synergism between gemcitabine and cisplatin.
van Moorsel CJ; Veerman G; Vermorken JB; Voorn DA; Kroep JR; Bergman AM; Pinedo HM; Peters GJ
Adv Exp Med Biol; 1998; 431():581-5. PubMed ID: 9598132
[No Abstract] [Full Text] [Related]
5. Induction of in vivo resistance against gemcitabine (dFdC, 2',2'-difluoro-deoxycytidine).
Ruiz van Haperen VW; Veerman G; van Moorsel CJ; Peters GJ
Adv Exp Med Biol; 1998; 431():637-40. PubMed ID: 9598143
[No Abstract] [Full Text] [Related]
6. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
Bergman AM; Pinedo HM; Jongsma AP; Brouwer M; Ruiz van Haperen VW; Veerman G; Leyva A; Eriksson S; Peters GJ
Biochem Pharmacol; 1999 Feb; 57(4):397-406. PubMed ID: 9933028
[TBL] [Abstract][Full Text] [Related]
7. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
[TBL] [Abstract][Full Text] [Related]
8. Interaction between cisplatin and gemcitabine in vitro and in vivo.
Peters GJ; Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Braakhuis BJ
Semin Oncol; 1995 Aug; 22(4 Suppl 11):72-9. PubMed ID: 7481849
[TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy studies with gemcitabine.
van Moorsel CJ; Veerman G; Bergman AM; Guechev A; Vermorken JB; Postmus PE; Peters GJ
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-17-S7-23. PubMed ID: 9194475
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacology and pharmacogenetics of gemcitabine.
Wong A; Soo RA; Yong WP; Innocenti F
Drug Metab Rev; 2009; 41(2):77-88. PubMed ID: 19514966
[TBL] [Abstract][Full Text] [Related]
11. Concentration and time dependent growth inhibition and metabolism in vitro by 2',2'-difluoro-deoxycytidine (gemcitabine).
Ruiz van Haperen VW; Veerman G; Noordhuis P; Vermorken JB; Peters GJ
Adv Exp Med Biol; 1991; 309A():57-60. PubMed ID: 1789270
[No Abstract] [Full Text] [Related]
12. Reduction of ara-C cytotoxicity in HL 60 cells by addition of deoxycytidine, cytidine or increased level of cytidine deaminase.
Mejer J; Mortensen BT
Adv Exp Med Biol; 1989; 253B():335-9. PubMed ID: 2558539
[No Abstract] [Full Text] [Related]
13. The role of deoxycytidine kinase in gemcitabine cytotoxicity.
van der Wilt CL; Kroep JR; Bergman AM; Loves WJ; Alvarez E; Talianidis I; Eriksson S; van Groeningen CJ; Pinedo HM; Peters GJ
Adv Exp Med Biol; 2000; 486():287-90. PubMed ID: 11783501
[No Abstract] [Full Text] [Related]
14. Cross-resistance of the gemcitabine resistant human ovarian cancer cell line AG6000 to standard and investigational drugs.
Bergman AM; Pinedo HM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Peters GJ
Adv Exp Med Biol; 1998; 431():587-90. PubMed ID: 9598133
[No Abstract] [Full Text] [Related]
15. In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model.
Kanzawa F; Saijo N
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-8-S7-16. PubMed ID: 9194474
[TBL] [Abstract][Full Text] [Related]
16. Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines.
Sakamoto Y; Yamagishi S; Okusaka T; Ojima H
Cells; 2019 Sep; 8(9):. PubMed ID: 31484399
[TBL] [Abstract][Full Text] [Related]
17. Study of apoptosis induction and deoxycytidine kinase/cytidine deaminase modulation in the synergistic interaction of a novel ceramide analog and gemcitabine in pancreatic cancer cells.
Giovannetti E; Leon LG; Bertini S; Macchia M; Minutolo F; Funel N; Alecci C; Giancola F; Danesi R; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):419-26. PubMed ID: 20544530
[TBL] [Abstract][Full Text] [Related]
18. [In vitro evaluation of potentially effective gemcitabine combination therapy for exocrine pancreatic carcinoma].
Kreil A; Bauer J; Scheithauer W
Acta Med Austriaca; 1999; 26(3):93-100. PubMed ID: 10520377
[TBL] [Abstract][Full Text] [Related]
19. Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.
van Haperen VW; Veerman G; Vermorken JB; Pinedo HM; Peters G
Biochem Pharmacol; 1996 Apr; 51(7):911-8. PubMed ID: 8651941
[TBL] [Abstract][Full Text] [Related]
20. Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.
Al-Madhoun AS; van der Wilt CL; Loves WJ; Padron JM; Eriksson S; Talianidis I; Peters GJ
Biochem Pharmacol; 2004 Aug; 68(4):601-9. PubMed ID: 15276067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
